FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

New MS Tx Could Offer Neuroprotection for MS Patients






















Researchers from the University of Alberta have identified a new approach for the treatment of multiple sclerosis (MS) by reducing inflammation in the brain, according to a study published in the Journal of Neuroinflammation.

Currently, most treatments for MS target the immune system to reduce brain inflammation. However, stronger medications suppress the immune system which causes some patients to experience major side effects. For the study, scientists analyzed granzyme B as a possible enzyme target to reduce inflammation, without significantly suppressing the immune system. They found that by suppressing granzyme B through a recent agent called serpina3n, they were able to significantly reduce the progression of MS symptoms in pre-clinical and human models.

RELATED: Can Estrogen Help Cut Relapses in Multiple Sclerosis?

Targeting granzyme B can block the damage that "induces the neurodegeneration in this disease, and the neurodegeneration strongly correlates with the disability," explained senior author Fabrizio Giuliani. "The body's inflammatory response is minimally impacted." By targeting the early stages of brain inflammation in patients with MS, the disease progression can be slowed, Giuliani explained.

https://ssl.gstatic.com/ui/v1/icons/mail/images/cleardot.gifResearchers are looking to prepare trials using human analogues of serpina3n that will further demonstrate the affects of granzyme B inhibition in MS patients. Neuroprotection may decrease the rate of disability that is tied to brain inflammation in patients with MS.

For more information visit med.ualberta.ca.

Story Source: The above story is based on materials provided by MPR
Note: Materials may be edited for content and length 
Click here to read original article


Go to Newer News Go to Older News